Metreleptin: Phase I started

Amylin began an open-label, U.S. Phase I trial in 12-15 Type I diabetics to evaluate twice-daily metreleptin plus insulin therapy for 5 months. The Juvenile Diabetes Research Foundation (JDRF) will pr...